ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2026
SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to Osimertinib
Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SMK-002, a novel derivative of proguanil, has higher inhibitory activity against cancer than proguanil. We previously found that SMK-002 significantly inhibited the proliferation of bladder cancer (BC) cells. In this study, we creatively found that the sensitivity of BC cells to SMK-002 was positively correlated with the expression of epidermal growth factor receptor (EGFR). Mechanistically, SMK-002 specifically targeted EGFR and inhibited its binding to the deubiquitination protein USP11, facilitated the ubiquitination degradation of EGFR in lysosomes by post-translational modification. Further studies suggested that SMK-002 significantly inhibited the p-EGFR/p-c-Raf/p-ERK downstream pathway. Osimertinib, one commonly used representative of the clinically approved third-generation EGFR inhibitors, has been rarely reported to apply on BC. Furthermore, we found that SMK-002 synergized with Osimertinib further downregulated EGFR signal pathway and reduced growth of BC both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.